Truist Securities Reiterates Buy Rating on Revolution Medicines, Inc. (RVMD)

Market Context

Revolution Medicines, Inc. operates in the Healthcare sector. The stock currently trades at $187.28 with a market capitalization of $15.2B. The stock has gained 394.5% over the past 52 weeks.

Analyst coverage from Truist Securities provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Revolution Medicines, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Revolution Medicines, Inc.

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 30, 2026	Truist Securities	Buy	N/A
Jun 29, 2026	Needham	Buy	N/A
Jun 10, 2026	Evercore ISI Group	Outperform	N/A
Jun 02, 2026	RBC Capital	Outperform	N/A
Jun 01, 2026	HC Wainwright & Co.	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View RVMD Stock Page